Clinical Monitoring and Safety
Cross-source consensus on Clinical Monitoring and Safety from 1 sources and 6 claims.
1 sources · 6 claims
Risks & contraindications
Interactions
Other
Highlighted claims
- GLP-1 receptor agonists and SGLT2 inhibitors are stopped one week before the low-energy diet begins. — Combining structured exercise with a low-energy diet to attenuate lean mass loss in South Asian adults living with type 2 diabetes: the COMBINE randomised trial protocol
- All other glucose-lowering therapies are stopped on the day the diet begins. — Combining structured exercise with a low-energy diet to attenuate lean mass loss in South Asian adults living with type 2 diabetes: the COMBINE randomised trial protocol
- Serious adverse events are reported to the sponsor within 24 hours. — Combining structured exercise with a low-energy diet to attenuate lean mass loss in South Asian adults living with type 2 diabetes: the COMBINE randomised trial protocol
- Before intervention starts, a study physician reviews glucose-lowering and blood-pressure-lowering medications. — Combining structured exercise with a low-energy diet to attenuate lean mass loss in South Asian adults living with type 2 diabetes: the COMBINE randomised trial protocol
- Clinical monitoring includes weekly reviews of capillary glucose, home blood pressure, and weight readings at defined intervention and reintroduction weeks. — Combining structured exercise with a low-energy diet to attenuate lean mass loss in South Asian adults living with type 2 diabetes: the COMBINE randomised trial protocol
- Common adverse events in low-energy diet trials include constipation, headache, dizziness, fatigue, and thirst. — Combining structured exercise with a low-energy diet to attenuate lean mass loss in South Asian adults living with type 2 diabetes: the COMBINE randomised trial protocol